Navigation Links
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
Date:6/17/2008

CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study will involve up to fifty-three subjects with SP-MS who will receive the drug once weekly in four escalating-dose cohorts. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in multiple sclerosis patients in early 2009.

"While the primary goal of this study is to demonstrate safety of PI-2301 in multiple sclerosis patients, we believe that this clinical trial is one of the most comprehensive looks at the pharmacologic effects of any immunomodulator in patients suffering from autoimmune diseases," stated Thomas P. Mathers, President and CEO of Peptimmune. Mr. Mathers will be presenting an overview of the PI-2301 clinical program at the BIO 2008 Business Forum, Wednesday, June 18th, at 9:00 a.m. PDT at the San Diego Convention Center, Room 2.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechan
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
4. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
5. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
6. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
7. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  Heated dialogue in recent months about ... cancer treatments to Gilead,s new hepatitis C drug Harvoni® ... world questioning what it means to put a price ... And while drug pricing is one of the ... both a general business and ethical standpoint – it ...
(Date:11/21/2014)... 21, 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... Technology Award for Vision, Innovation, and Leadership has been awarded ... This award recognizes an individual who has had a significant ... for several decades. "I am honored ... Stuart Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When ...
(Date:11/21/2014)... Clementia Pharmaceuticals, Inc.  announced ... has granted Orphan Medicinal Product Designation for ... the treatment of fibrodysplasia ossificans progressiva (FOP). ... disease characterized by painful, recurrent episodes of ... bone formation. This process, known as heterotopic ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 “Due ... cane,” said an inventor, from Gurnee, Ill. “While using the ... could be and I thought there needed to be a ... He invented the SPIKE BLOCK. , The SPIKE BLOCK offers ... doing so, it would help to reduce injuries and damage ...
(Date:11/22/2014)... In order to provide better services, LunaDress has updated ... The business knows that a suitable cocktail party dress is ... Now, the party dresses supplier’s high quality items are offered ... company in fashion industry, LunaDress understands that it is not ... it always raises the professional level and innovation ability. The ...
(Date:11/22/2014)... 22, 2014 "My friend went in ... by the machine," said an inventor from Cambria Heights, ... go back a second time because the first results ... She developed the patent-pending MAMO EASY to offer a ... design saves the patient from the pain normally involved ...
(Date:11/22/2014)... Domestic farmgate milk and dairy ... due to a fall in demand for ... amid the global financial crisis. However, these declines ... dairy manufacturers on the international scene. Strong growth ... growth, primarily due to supply constraints in some ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication ... The article states that, “While they give off the appearance ... go into creating this powerful look.” , One of the ... choosing which kind of block matches your home environment and ... “The two main options are concrete and stone blocks. But ...
Breaking Medicine News(10 mins):Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2
... The Health Coalition on Liability and Access released a ... on the state and federal level. The report detailed ... passed laws limiting non-economic damages, while also acknowledging the ... to be enacted and is unlikely in the 111th ...
... are many targets now for interfering with the process , , ... from infected to uninfected immune system T-cells has been captured ... could lead to new ways to block the transmission of ... have focused on free- roaming viruses, but this study shows ...
... Test drives of the Simulated Impaired Driving Experience(R), (SIDNE(R)), ... be attending the Lifesavers conference at the Gaylord Opryland ... 30 and 31. The Lifesavers Conference is a national ... injuries on our nation,s roadways. "We are excited to ...
... Urged to Register with Safe and Well WASHINGTON, March 27 ... North Dakota and Minnesota today to staff shelters that will be ... levees as it rises to record heights. Projections are that the ... feet above flood stage, and the National Weather Service reports water ...
... 27 Zydus Pharmaceuticals announced today that it has ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) ... This product is available for immediate shipment.Topiramate tablets ... years old or older with partial onset or primary ...
... NYU School of Medicine have been named Early Career ... honorees, Iannis Aifantis, Ph.D. associate professor of pathology, co-director ... Cancer Institute and Jeremy S. Dasen Ph.D., assistant professor ... are among 50 of the nation,s top scientists being ...
Cached Medicine News:Health News:HCLA Releases Report on Status of Medical Liability Reform 2Health News:Scientists Capture HIV Transfer Among T-Cells on Video 2Health News:Innocorp, ltd. to Attend Lifesavers Conference 2Health News:Red Cross Readies Shelters As Flood Waters Threaten to Top Levees 2Health News:2 NYU scientists named Howard Hughes Medical Institute's Early Career Scientists 2Health News:2 NYU scientists named Howard Hughes Medical Institute's Early Career Scientists 3
... CARDIAC proBNP assay is a rapid and accurate ... reader system assisting the diagnosis and assessment of ... is both speed and accuracy profit ... CARDIAC proBNP assay = 12 minutes. In emergency ...
The SJM Sguin annuloplasty ring, a semi-rigid ring, is constructed of a one-piece solid core of ultra-high-weight polyethylene enclosed in a knitted polyester sewing cuff....
Intermittent catheter...
... to a new dimension in vitreoretinal ... tool composed of purified perfluoro-n-octane, you ... Perfluoron is ideal for managing retinal ... retinal tears and trauma. , ,Certified ...
Medicine Products: